Proteomics International LaboratoriesLtd
Proteomics International Laboratories Ltd is an Australia-based medical technology company.
The business
Proteomics International Laboratories Ltd is an Australia-based medical technology company. The Company is engaged in predictive diagnostics and bioanalytical services. It specializes in the area of proteomics, the industrial scale study of the structure and function of proteins. It focuses on developing and commercializing diagnostic tests for chronic diseases. Its principal activities fall into three key areas: commercialization of PromarkerD, the predictive test for diabetic kidney disease (DKD) and future kidney function decline in patients with type 2 diabetes; precision diagnostic tests in development: the Promarker pipeline, and specialist accredited analytical services on a commercial basis. Its Promarker pipeline and analytical services include PromarkerEndo, PromarkerEso and OxiDx technology. PromarkerEndo is a prototype diagnostic test for endometriosis identifying up to 90% of patients with the disease. PromarkerEso is a prototype diagnostic test for esophageal cancer.
Small Caps Research
No research on Proteomics International LaboratoriesLtd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise PIQ based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Proteomics International Laboratories Secures Australian Patent Acceptance for PromarkerEndo
Proteomics International wins IP Australia acceptance for PromarkerEndo, extending protection to 2041 and boosting local commercialization and licensing talks.
Proteomics International Appoints Healius Exclusive Australian Distributor for Promarker Blood Tests
Proteomics inks exclusive Australian distributor deal with Healius for Promarker blood tests, enabling nationwide rollout by 2027; revenue not yet estimable.
Proteomics International Labs Secures US Patent for PromarkerEndo Blood Test
Proteomics International wins US patent for PromarkerEndo endometriosis blood test, boosting licensing/partnering prospects and extending protection to 2041.
Proteomics International Obtains Canadian Patent for PromarkerEso Blood Test
Proteomics International Laboratories (ASX: PIQ) has secured new intellectual property protection in Canada, after the country’s Patent Office granted a patent for its PromarkerEso blood test for esophageal adenocarcinoma.
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.